Ono Pharmaceutical OPHLY Stock
Ono Pharmaceutical Price Chart
Ono Pharmaceutical OPHLY Financial and Trading Overview
| Ono Pharmaceutical stock price | 5.1 USD |
| Previous Close | 5.15 USD |
| Open | 5.24 USD |
| Bid | 5.26 USD x 110000 |
| Ask | 5.4 USD x 320000 |
| Day's Range | 5.24 - 5.36 USD |
| 52 Week Range | 3.71 - 5.75 USD |
| Volume | 40.17K USD |
| Avg. Volume | 41.21K USD |
| Market Cap | 7.61B USD |
| Beta (5Y Monthly) | 0.135 |
| PE Ratio (TTM) | 16.875 |
| EPS (TTM) | 0.31 USD |
| Forward Dividend & Yield | 0.17 (3.10%) |
| Ex-Dividend Date | March 31, 2026 |
| 1y Target Est | N/A |
OPHLY Valuation Measures
| Enterprise Value | -88992882688 USD |
| Trailing P/E | 16.875 |
| Forward P/E | 2.3788548 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.015093426 |
| Price/Book (mrq) | 1.33761 |
| Enterprise Value/Revenue | -0.176 |
| Enterprise Value/EBITDA | -0.643 |
Trading Information
Ono Pharmaceutical Stock Price History
| Beta (5Y Monthly) | 0.135 |
| 52-Week Change | 42.10% |
| S&P500 52-Week Change | 16.97% |
| 52 Week High | 5.75 USD |
| 52 Week Low | 3.71 USD |
| 50-Day Moving Average | 5.02 USD |
| 200-Day Moving Average | 4.97 USD |
OPHLY Share Statistics
| Avg. Volume (3 month) | 41.21K USD |
| Avg. Daily Volume (10-Days) | 71.46K USD |
| Shares Outstanding | 1.41B |
| Float | 1.36B |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.0050% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 80 |
| Trailing Annual Dividend Yield | 1553.39% |
| 5 Year Average Dividend Yield | 319.00% |
| Payout Ratio | 0.5239 |
| Last Split Factor | 3:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | March 31, 2027 |
Profitability
| Profit Margin | 15.11% |
| Operating Margin (ttm) | 26.38% |
| Gross Margin | 73.55% |
| EBITDA Margin | 27.43% |
Management Effectiveness
| Return on Assets (ttm) | 5.98% |
| Return on Equity (ttm) | 9.25% |
Income Statement
| Revenue (ttm) | 504.41B USD |
| Revenue Per Share (ttm) | 357.47 USD |
| Quarterly Revenue Growth (yoy) | -8.90% |
| Gross Profit (ttm) | 371.03B USD |
| EBITDA | 138.39B USD |
| Net Income Avi to Common (ttm) | 76.25B USD |
| Diluted EPS (ttm) | 0.32 |
| Quarterly Earnings Growth (yoy) | 36.70% |
Balance Sheet
| Total Cash (mrq) | 219.62B USD |
| Total Cash Per Share (mrq) | 155.64 USD |
| Total Debt (mrq) | 117.1B USD |
| Total Debt/Equity (mrq) | 13.42 USD |
| Current Ratio (mrq) | 3.283 |
| Book Value Per Share (mrq) | 4.037051 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 134.5B USD |
| Levered Free Cash Flow (ttm) | 120.53B USD |
Profile of Ono Pharmaceutical
| Country | United States |
| State | N/A |
| City | Osaka |
| Address | 8-2, Kyutaromachi 1-chome |
| ZIP | 541-8564 |
| Phone | 81 6 6263 5670 |
| Website | https://www.ono-pharma.com |
| Industry | Drug Manufacturers - General |
| Sector(s) | Healthcare |
| Full Time Employees | 4206 |
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has strategic collaboration with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; Congruence Therapeutics; and Aitia, Inc. for drug discovery of novel therapeutic targets for neurological diseases. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Q&A For Ono Pharmaceutical Stock
What is a current OPHLY stock price?
Ono Pharmaceutical OPHLY stock price today per share is 5.1 USD.
How to purchase Ono Pharmaceutical stock?
You can buy OPHLY shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ono Pharmaceutical?
The stock symbol or ticker of Ono Pharmaceutical is OPHLY.
Which industry does the Ono Pharmaceutical company belong to?
The Ono Pharmaceutical industry is Drug Manufacturers - General.
How many shares does Ono Pharmaceutical have in circulation?
The max supply of Ono Pharmaceutical shares is 1.41B.
What is Ono Pharmaceutical Price to Earnings Ratio (PE Ratio)?
Ono Pharmaceutical PE Ratio is 16.45161200 now.
What was Ono Pharmaceutical earnings per share over the trailing 12 months (TTM)?
Ono Pharmaceutical EPS is 0.31 USD over the trailing 12 months.
Which sector does the Ono Pharmaceutical company belong to?
The Ono Pharmaceutical sector is Healthcare.
